Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection

Immunology

Volumn 128, Issue 2, 2009, Pages 227-235

  Moorman, Jonathan ^a,b   Dong, Zhi P ^b   Ni, Lei ^b   Zhang, Chunlan ^b   Borthwick, Thomas ^a,b   Yao, Zhi Q ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b East Tennessee State University   (United States)

Author keywords

Autoimmunity; B cells; Hepatitis C; Suppressor of cytokine signalling 1 (SOCS 1); Tumour necrosis factor and Apo L related leucocyte expressed ligand 1 (TALL 1) BAFF BLYS

Indexed keywords

B CELL ACTIVATING FACTOR; CD69 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CORE PROTEIN; HEPATITIS B CORE ANTIGEN; PEGINTERFERON; RIBAVIRIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR;

ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MEMORY CELL; PHENOTYPE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELLS, CULTURED; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 69949132194     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03106.x     Document Type: Article

References (51)

1. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005 5 : 227 236.
2. Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, Dammacco F. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 2001 167 : 21 9.
3. King E, Trabue C, Yin D, Yao ZQ, Moorman JP, Hepatitis C. The complications of immune dysfunction. Expert Rev Clin Immunol 2007 3 : 145 157.
4. Fabris M, Quartuccio S, Sacco S et al. B-lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinemia syndrome and hepatitis C virus infection. Rheumatology 2007 46 : 37 43.
5. Moore PA, Belvedere O, Orr A et al. BLys: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999 285 : 260 263.
6. Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999 189 : 1747 1756.
7. Nardelli B, Belvedere O, Roschke V et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001 97 : 198 204.
8. Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001 166 : 6 10.
9. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001 44 : 1313 1319.
10. Mariette X, Roux S, Zhang J et al. The level of BLys (BAFF) correlates with the titer of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003 62 : 168 171.
11. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006 54 : 192 201.
12. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002 100 : 2973 2979.
13. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, Moore JP, Cerutti A. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006 176 : 3931 3941.
14. Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, Zuckerman E. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006 27 : 134 139.
15. Sene D, Limal P, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P. Hepatitis C virus-associated B-cell proliferation - the role of serum B lymphocyte stimulator (BLyS-BAFF). Rheumatology 2007 46 : 65 9.
16. Khare SD, Sarosi I, Xia XZ et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000 97 : 3370 3375.
17. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999 190 : 1697 1710.
18. Groom J, Kalled SL, Cutler AH et al. Association of BAFF-BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002 109 : 59 68.
19. Reyes SLI, Leon BF, Rozas VMF, Gonzalez JP, Naves PR. BAFF: a regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer. Rev Med Chil 2006 134 : 1175 1184.
20. Yao ZQ, Prayther D, Trabue C, Dong ZP, Moorman J. Differential regulation of SOCS-1 signaling in B and T lymphocytes by HCV core protein. Immunology 2008 125 : 197 207.
21. Yao ZQ, King E, Prayther D, Yin D, Moorman J. T cell dysfunction by hepatitis C virus core protein involves PD-1-PDL-1 signaling. Viral Immunol 2007 20 : 276 287.
22. Golden-Mason L, Klarquist J, Wabed AS, Rosen HR. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 2008 180 : 3637 3641.
23. Vallat L, Benhamou Y, Gutierrez M et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004 50 : 3668 3678.
24. Clifford BD, Donahue D, Smith L et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995 21 : 613 619.
25. Zachou K, Liaskos C, Christodoulou DK et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003 33 : 161 168.
26. Germanidis G, haioun C, Dhumeaux D, Reyes F, Pawlotsky JM. Hepatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma. Hepatology (Baltimore, MD) 1999 30 : 822 823.
27. Kashyap A, Nademanee A, Molina A. Hepatitis C and B-cell lymphoma. Ann Intern Med 1998 128 : 695.
28. Ohsawa M, Shingu N, Miwa H et al. Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection. Int J Cancer 1999 80 : 237 239.
29. Agnello V. Hepatitis C virus infection and type II cryoglobulinemia: an immunological perspective. Hepatology (Baltimore, MD) 1997 26 : 1375 1379.
30. Ferri C, Greco F, Longombardo G et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991 34 : 1606 1610.
31. Franzin F, Efremov DG, Pozzato G, Tulissi P, Batista F, Burrone OR. Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br J Haematol 1995 90 : 548 552.
32. Vallat L, Benhamou Y, Gutierrez M et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004 50 : 3668 3678.
33. D'Amico E, Chincoli C, Cacciatore P et al. Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study. Dig Dis Sci 2005 50 : 2344 2347.
34. Mazzaro C, Zorat F, Caizzi M et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005 42 : 632 638.
35. Mazzaro C, Zorat F, Comar C et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 2003 30 : 1775 1781.
36. Zaja F, De Vita S, Russo D, Michelutti A, Fanin R, Ferraccioli G, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002 46 : 2252 2254.
37. Maillard P, Krawczynski K, Nitkiewicz J et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol 2001 75 : 8240 8250.
38. Masalova OV, Atanadze SN, Samokhvalov EI et al. Detection of hepatitis C virus core protein circulating within different virus particle populations. J Med Virol 1998 55 : 1 6.
39. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF-BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003 171 : 5215 5224.
40. Rodriguez B, Valdez H, Freimuth W, Butler T, Asaad R, Lederman MM. Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. AIDS 2003 17 : 1983 1985.
41. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000 106 : 1239 1249.
42. Yao ZQ, Nguyen DT, Hiotellis AI, Hahn YS. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J Immunol 2001 167 : 5264 5272.
43. Yao ZQ, Eisen-Vandervelde A, Ray S, Hahn YS. HCV core-gC1qR interaction arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1. Virology 2003 314 : 271 282.
44. Yao ZQ, Eisen-Vandervelde A, Waggoner SN, Cale EM, Hahn YS. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J Virol 2004 78 : 6409 6419.
45. Levine JW, Gota C, Fessler B, Valabrese L, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005 32 : 1164 1167.
46. La Civita L, Zignego AL, Lombardini F et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol 1996 23 : 1641 1643.
47. Beuthien W, Mellinghoff HU, Kempis J. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005 24 : 507 515.
48. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev 2002 2 : 410 416.
49. Yamamoto M, Nishimoto N, Davydova J, Kishimoto T, Curiel DT. Suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cells. Cancer Gene Ther 2006 13 : 194 202.
50. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 2004 23 : 7726 7733.
51. Komazaki T, Nagai H, Emi M et al. Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK-STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 2004 34 : 191 194.